Roche: FDA expands field of application for anti-covid drug
(CercleFinance.com) - Roche announced on Monday that its partner Regeneron has received approval from the US health authorities (FDA) for a new indication for its anti-covid-19 cocktail.
The FDA emergency approval now includes prophylactic use in people at high risk of severe Covid who have not been fully vaccinated and who have been exposed to an infected person.
The approval also covers people who are at high risk of exposure to an infected person in institutions such as nursing homes and prisons.
For the record, Roche is collaborating with Regeneron in this program, which combines two of the US group's compounds (casirivimab and imdevimab).
Copyright (c) 2021 CercleFinance.com. All rights reserved.